Integration of combinatorial chemistry and structure-based drug design

Current Opinion in Drug Discovery and Development

Volumn 2, Issue 3, 1999, Pages 224-233

  Antel, Jochen ^a  

^a Solvay Pharmaceuticals GmbH   (Germany)

Author keywords

Library based design; Structure based design; Targeted libraries

Indexed keywords

HORMONE RECEPTOR STIMULATING AGENT; L 264930; L 363377; L 373722; L 377009; L 779976; L 796778; L 797591; L 803087; L 817818; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; SOMATOSTATIN; SOMATOSTATIN RECEPTOR; THROMBIN; THROMBIN INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL STRUCTURE; CHEMISTRY; DATA BASE; DRUG DESIGN; MOLECULAR MODEL; STRUCTURE ANALYSIS; SYNTHESIS;

EID: 0033044392     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (87)

1. Furka A: Studies on possibilities of systematic searching for pharmaceutically useful peptides. Notariell Beglaubigtes Dokument Nr 36237/1982, Budapest, Hungary (1982).
2. Geysen HM, Meloen RH, Barteling SJ: Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acids. Proc Natl Acad Sci USA (1984) 81:3998-4002.
3. Houghten RA: General method for the rapid solid-phase synthesis of large numbers of peptides: specificity of antigen-antibody interaction at the level of individual amino acids. Proc Natl Acad Sci USA (1985) 82:5131-5135.
4. Zuckermann RN, Martin EJ, Spellmeyer DC, Stauber GB, Shoemaker KR, Kerr JM, Figliozzi GM, Goff DA, Siani MA, Simon RJ, Banville SC, Brown EG, Wang L, Richter LS, Moos WH: Discovery of nanomolar ligands for 7-transmembrane G-protein-coupled receptors from a diverse N-(substituted)glycine peptoid library. J Med Chem (1994) 37:2678-2685.
5. Thompson LA, Ellman JA: Synthesis and application of small molecule libraries. Chem Rev (1996) 96:555-600.
6. Terrett NK, Gardner M, Gordon DW, Kobylecki RJ, Steele J: Combinatorial synthesis: the design of compound libraries and their application to drug discovery. Tetrahedron (1995) 51:8135-8173.
7. Balkenhohl F, von dem Bussche-Hünnefeld C, Lansky A, Zechel C: Combinatorial synthesis of small organic molecules. Angew Chem Int Ed Engl (1996) 35:2289-2337.
8. Gubemator K, Böhm HJ (Eds): Structure-based ligand design. Wiley-VCH, Weinheim (1998).
9. Kubinyi H: Structure-based design of enzyme inhibitors and receptor ligands. CurrOpinDrugDiscovDev(199B) 1:4-15.
10. Recent review with many references of successful examples, including those that have already reached the market.
11. Amzel LM: Structure-based drug design. Curr Opin B/oteC/7/70/(1998) 9:366-369.
12. Babine RE, Bender SL: Molecular recognition of proteinligand complexes: applications to drug design. Chem Rev (1997) 97:1359-1472.
13. Vacca JP, Condra JH: Clinically effective HIV-1 protease inhibitors. Drug Discovery Today (1997) 2:261-272.
14. Gallop MA, Barren RW. Dower WJ, Fodor SPA, Gordon EM: Applications of combinatorial technologies to drug discovery. 1. Background and peptide combinatorial libraries. J Med Chem (1994) 37:1233-1251.
15. Gordon EM, Barrett RW. Dower WJ, Fodor SPA, Gallop MA: Applications of combinatorial technologies to drug discovery. 2. Combinatorial organic synthesis, library screening strategies, and future directions. J Med Chem (1994)37:1385-1401.
16. Willett P (Ed): Persp Drug Discov Design. Kluwer/Escom, Dordrecht, The Netherlands (1997) 7/8.
17. Martin YC: Challenges and prospects for computational aids to molecular diversity. Persp Drug Discov Design (1997) 7/8:159-172.
18. Martin EJ, Blaney JM, Siani MA, Spellmeyer DC, Wong AK, Moos WH: Measuring diversity: experimental design of combinatorial libraries for drug discovery. J Med Chem (1995) 38:1431-1436.
19. Brown RD: Descriptors for diversity analysis. Persp Drug Discov Design (1997) 7/8:31 -49.
20. Patterson DE, Cramer RD, Ferguson AM, Clark RD, Weinberger LE: Neighborhood behavior: a useful concept for validation of 'molecular diversity' descriptors. J Med Chem (1996) 39:3049-3059.
21. Matter H: Selecting optimally diverse compounds from structure databases: a validation study of two-dimensional and three-dimensional molecular descriptors. J Med Chem (1997) 40:1219-1229.
22. Comprehensive, comparative discussion of 2-D and 3-D descriptors for diversity analysis.
23. Pötter T, Matter H: Random or rational design? Evaluation of diverse compound subsets from chemical structure databases. J Med Chem (1998) 41:478-488.
24. Pickett SD, Mason JS, McLay IM: Diversity profiling and design using 3D pharmacophores: pharmacophore derived queries (PDQ). J Chem Inf Comput Sci (1996) 36:1214-1223.
25. Brown RD, Martin YC: Use of structure-activity data to compare structure-based clustering methods and descriptors for use in compound selection. J Chem Inf Comput Sci (1996) 36:572-584.
26. Kauvar LM, Higgins DL, Villar HO, Sportsman JR, Engqvist-Goldstein A, Bukar R, Bauer KE, Dilley H, Rocke DM; Predicting ligand binding to proteins by affinity finger-printing. CDeme/o/(1995) 2:107-118.
27. Briem H, Kuntz ID: Molecular similarity based on DOCK generated fingerprints. J Med Chem (1996) 39:3401-3408.
28. Kubinyi H: Combinatorial and computational approaches in structure-based drug design. Curr Opin Drug Discov Dev (1998) 1:16-27.
29. Excellent review related to the present one. Several successful examples are cited.
30. Kubinyi H: Similarity and dissimilarity: a medicinal chemist's view. In: 3D OSAR in drug design. Volume 2. Ligand-protein interactions and molecular similarity, Kubinyi H, Folkers G, Martin YC (Eds). Kluwer Academic Publishers, Dordrecht (1998):225-252.
31. Gordon EM, Kerwin JF (Eds): Combinatorial chemistry and molecular diversity in drug discovery. John Wiley & Sons, New York (1998).
32. Doyle PM: Combinatorial chemistry in the discovery and development of drugs. J Chem Technol Biotechnol (1995) 64:317-324.
33. Peisach E, Casebier D, Gallion SL, Furth P, Petsko GA, Hogan JC Jr, Ringe D: Interaction of a peptidomimetic aminimide inhibitor with elastase. Science (1995) 269:66-69.
34. Beutel BA: Discovery and identification of lead compounds from combinatorial mixtures. Ann Rep Med Chem (1997) 32:261-268.
35. Greer J, Erickson JW, Baldwin JJ, Vamey MD: Application of three-dimensional structures of protein target molecules in structure-based drug design. J Med Chem (1994) 37:1035-1054.
36. Tame JHR: Scoring functions: a view from the bench. J Comput-Aided Mol Design (1999) 13:99-108.
37. Ewing TJA, Kuntz ID: Critical evaluation of search algorithms for automated molecular docking and database screening. J Comput Chem (1997) 18:1175-1189.
38. Describes improvements of version 4.0 of the DOCK program.
39. Antel J, Reuter I, Schomburg D: On the benefits of attractive pseudo-potentials in a genetic algorithm approach for structure-based library screening. In: Computer-assisted lead finding and optimization. Van de Waterbeemd H, Testa B, Folkers G (Eds), Verlag Helvetica Chimica Acta, Basel (1997).
40. Müller K (Ed): Persp Drug Discov Design. Kluwer/Escom, Dordrecht, The Netherlands (1995) 3.
41. Davis AM, Teague SJ: Hydrogen bonding, hydrophobic interactions, and failure of the rigid receptor hypothesis. Angew Chem Inl Ed Engl (1999) 38:736-749.
42. Gutin AM, Abkevich VI, Shakanovich El: Is burst hydrophobic collapse necessary for protein folding? Biochemistry (1995) 34:3066-3076.
43. Desai MC, Vincent LA, Rizzi JP: Importance of parallel vectors and 'hydrophobic collapse' of the aligned aromatic rings: discovery of a potent substance P antagonist. J Med Chem (1994) 37:4263-4266.
44. Boehm HJ, Klebe G, Kubinyi H: Wirkstoffdesign. Spektrum Akademischer Verlag, Heidelberg (1996).
45. Antel J: Structure-based drug design versus combinatorial chemistry; contradiction or complementarity. Abstracts, XlVth International Symposium on Medicinal Chemistry, Maastricht, The Netherlands (1996):Abs P-12.01.
46. Bone R, Salemme FR: The integration of structure-based design and directed combinatorial chemistry for new pharmaceutical discovery. In: Structure-based drug design, Veerapandian P (Ed). Marcel Dekker, New York (1997):525-539.
47. Salemme FR, Spurtino J, Bone R: Serendipity meets precision: the integration of structure-based drug design and combinatorial chemistry for efficient drug discovery. Structure (1997) 5:319-324.
48. Martin EJ, Spellmeyer DC, Critchlow RE Jr, Blaney JM: Does combinatorial chemistry obviate computer-aided drug design? Rev Comp Chem (1997) 10:75-100.
49. Ghose AK, Viswanadhan VN, Wendoloski JJ: A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases. J Comb Chem (1998) 1:55-68.
50. Sadowski J, Kubinyi H: A scoring scheme for discriminating between drugs and nondrugs. J Med Chem (1998) 41:3325-3329.
51. D and 2-D parameters were used to train a neuronal network to discriminate between drugs and non-drugs. See also the related reference [49].
52. Martin EJ, Critchlow RE: Beyond mere diversity: tailoring combinatorial libraries for drug discovery. J Comb Chem (1998) 1:32-45.
53. Antel J: Integration of combinatorial chemistry and structure-based drug design. Abstracts, CHI-conference: Strategies and techniques for identification of novel bioactive compounds, Zurich, Switzerland (1998).
54. Ajay A, Walters WP, Murcko MA: Can we learn to distinguish between 'drug-like' and 'nondrug-like' molecules? J Med Chem (1998) 41:3314-3324.
55. Illig C, Eisennagel S, Bone R, Radzicka A, Murphy L, Rändle T, Spuriino J, Jaeger E, Salemme FR, Soll RM: Expanding the envelope of structure-based drug design using chemical libraries: application to small-molecule inhibitors of thrombin. Med Chem Res (1998) 8:244-260.
56. Boehm HJ, Banner DW. Weber L: Combinatorial docking and combinatorial chemistry: Design of potent non-peptide thrombin inhibitors. J Comput-Alded Mol Design (1999) 13:51-56.
57. Brady SF, Stauffer KJ, Lumma WC, Smith GM, Ramjit HG, Lewis SD, Lucas BJ, Gardell SJ, Lyle EA, Appleby SD, Cook JJ, Holahan MA, Stranieri MT, Lynch YJ Jr, Lin JH, Chen IW, Vastag K, Naylor-Olsen AM, Vacca JP: Discovery and development of the novel potent orally active thrombin inhibitor W-(9-hydroxy-9-fluorenecarboxy)prolyl trans-4aminocyclohexylmethyl amide (L-372460): Coapplication of structure-based design and rapid multiple analogue synthesis on solid support. J Med Chem (1998) 41:401-406.
58. Antel J: Integration of structure-based drug design, combinatorial chemistry and high throughput screening: a Key for success in lead finding and optimization. Abstracts, International symposium: Speeding up drug discovery. Schliersee, Germany (1998).
59. Lewell XQ, Smith R: Drug-motif-based diverse monomer selection: method and application in combinatorial chemistry. J Mol Graph Model (1997) 15:43-48.
60. Kim. CD, Lew W, Williams MA, Liu H, Zhang L, Swaminathan S, Bischofberger N. Chen MS, Mendel DB, Tai CY. Laver WG, Stevens RC: Influenza neuraminidase inhibitors possessing a novel Hydrophobie interaction in the enzyme active site: design, synthesis and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. JAm Chem Soc (1997) 119:681-690.
61. Bystroff C, Kraut J: Crystal structure of unliganded Escherichia coli dihydrofolate reductase. Ligand-induced conformational changes and cooperativity in binding. Biochemistry (1991) 30:2227-2239.
62. Brandstetter H, Turk D, Hoeffken HW, Grosse D, Sturzebecher J, Martin PO, Edwards BF, Bode W: Refined 2.3 A X-ray crystal structure of bovine thrombin complexes formed with the benzamidine and arginine-based thrombin inhibitors NAPAP, 4-TAPAP and MQPA. A starting point for improving antithrombotics. J Mol Biol (1992) 226:1085-1099.
63. Strickland CL, Fevig JM, Galemmo RA Jr, Wells BL, Kettner CA, Weber PC: Biochemical and crystallographic characterization of homologous non-peptidic thrombin inhibitors having alternate binding modes. Acta Crystallogr D Biol Crystallogr (1998) 54(Pt 6 No 2):1207-1215.
64. Pavone V, De Simone G, Nastri F, Galdiero S, Staiano N, Lombardi A, Pedone C: Multiple binding mode of reversible synthetic thrombin inhibitors. A comparative structural analysis. Biol Chem (1998) 379(8-9):987-1006.
65. Schulze-Gahmen U, Brandsen J, Jones HD, Morgan DO, Meijer L, Vesely J, Kim SH: Multiple modes of ligand recognition: crystal structures of cyclin-dependent protein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopentenyladenine. Proteins (1995) 22(4):378-391.
66. Stout TJ, Sage CR, Stroud RM: The additivity of substrate fragments in enzyme-ligand binding. Structure (1998) 6(7):839-848.
67. Mattos C, Rasmussen B, Ding X, Petsko GA, Ringe D: Analogous inhibitors of elastase do not always bind analogously. Nat Struct Biol (1994) 1:55-58.
68. Roderick SL, Foumie-Zaluski MC, Roques BP, Matthews BW: Thiorphan and retro-thiorphan display equivalent interactions when bound to crystalline thermolysin. Biochemistry (1989) 28:1493-1497.
69. Boehm HJ, Klebe G: What can we learn from molecular recognition in protein-ligand complexes for the design of new drugs? Angew Chem Int Ed Engl (1996) 35:2589-2614.
70. Dolle RE: Discovery of enzyme inhibitors through combinatorial chemistry. Mol Divers (1996) 2:223-236.
71. Jiracek J, Yiotakis A, Vincent B, Lecoq A, Nicolaou A, Checler F; Dive V: Development of highly potent and selective phosphinic peptide inhibitors of zinc endopeptidase 24-15 using combinatorial chemistry. J Bio/ Chem (1995) 270:21701-21706.
72. Jiracek J, Yiotakis A, Vincent B, Checler F; Dive V: Development of the first potent and selective inhibitor of the zinc endopeptidase neurolysin using a systematic approach based on combinatorial chemistry of phosphinic peptides. JBiol Chem (1996) 271:19606-19611.
73. Norman TC, Gray NS, Koh JT, Schultz PG: A structure-based library approach to kinase inhibitors. J Am Chem Soc (1996) 118:7430-7431.
74. Uoyd J, Schmidt JB, Hunt JT, Barrish JC, Little DK, Tymiak AA: Solid phase synthesis of phosphinic acid endothelin converting enzyme inhibitors. Bioorg Med Chem Lett (1996) 6:1323-1326.
75. Murphy MM, Schullek JR, Gordon EM, Gallop MA: Combinatorial organic synthesis of highly functionalized pyrrolidines: Identification of a potent angiotensin converting enzyme inhibitor from a mercaptoacyl proline library. JAm Chem Soc (1995) 117:7029-7030.
76. Foley MA, Hassman AS, Drewry DH, Gréer DG, Wagner CD, Feldman PL, Berman J, Bickett DM, McGeeham GM, Lambert MH, Green M: Rapid synthesis of novel dipeptide inhibitors of human collagenase and gelatinase using solid phase chemistry. Bioorg Med Chem Lett (1996) 6:1905-1910.
77. Wiley RM, Fisher MJ: Small-molecule direct thrombin inhibitors. Exp Opin Ther Patents (1997) 7:1265-1282.
78. Ripka WC, Vlasuk GP: Antithrombotics/serine proteases. Annu Rep Med Chem (1997) 32(8):71-89.
79. Lumma WC Jr, Witherup KM, Tucker TJ, Brady SF, Sisko JT, Naylor-Olsen AM, Lewis SD, Lucas BJ, Vacca JP: Design of novel, potent, noncovalent inhibitors of thrombin with nonbasic P-1 substructures: rapid structure-activity studies by solid-phase synthesis. J Med Chem (1998) 41:1011-1013.
80. Rockwell A, Melden M, Copeland RA, Hardman K, Decicco CP, DeGrado WF: Complementarity of combinatorial chemistry and structure-based ligand design: application to the discovery of novel inhibitors of matrix metalloproteinases. J AmChem Soc (1996) 118:10337-10338.
81. Szardenings AK, Harris D, Lam S, Shi L, Tien D, Wang Y, Patel DV, Navre M, Campbell DA: Rational design and combinatorial evaluation of enzyme inhibitor scaffolds: identification of novel inhibitors of matrix metalloproteinases. J Med Chem (1998) 41:2194-2200.
82. Trumpp-Kallmeyer S, Hoflack J, Bruinvels A, Hibert M: Modeling of G-protein-coupled receptors: application to dopamine, adrenaline, serotonin, acetylcholine, and mammalian opsin receptors. J Med Chem (1992) 35:3448-3462.
83. Höltje HD, Folkers G: Molecular Modeling. Basic principles and applications. VCH, Weinheim (1996).
84. Kopple KD, Baures PW, Bean JW, D'Ambrosio CA, Hughes JL, Peishoff CE, Eggleston DS: Conformations of Arg-Gly-Asp containing heterodetic cyclic peptides: - solution and crystal studies. JAm Chem Soc (1992) 114:9615-9623.
85. Ku TW, All FE, Barton LS. Bean JW. Bondinell WE, Burgess JL, Callahan JF, Calvo RR, Chen L, Eggleston DS, Gleason JG, Huffman WF, Hwang SM, Jakas DR, Karash CB, Keenan RM, Kopple KD, Miller WH, Newlander KA, Nichols A, Parker MF, Peishoff CE, Samanen JM, Uzinskas I, Venslavsky JW: Direct design of a potent non-peptide fibrinogen receptor antagonist based on the structure and conformation of a highly constrained cyclic RGD peptide. J Am Chem Soc (1993)115:8861-8862.
86. Rohrer SP, Birzin ET, Mosley RT, Berk SC. Hutchins SM, Shen D-M, Xiong Y. Hayes EC, Parmar RM, Foor F, Mitra SW, Degrado SJ, Shu M, Klopp JM, Cai S-J, Blake A, Chan WWS, Pasternak A, Yang L, Patchett AA, Smith RG, Chapman KT, Schaeffer JM: Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. Science (1998) 282:737-740.
87. Yang L, Berk SC, Rohrer SP, Mosley RT, Quo L, Underwood DJ, Arison BH, Birzin ET, Hayes EC, Mitra SW, Parmar RM, Cheng K, Wu TJ, Butler BS, Foor F, Pasternak A, Pan Y, Silva M, Freidinger RM, Smith RG. Chapman K, Schaeffer JM, Patchett AA: Synthesis and biological activities of potent peptidomimetics selective for somatostatin receptor subtype 2. Proc NatlAcad Sci USA (1998) 95:10836-10841.